Therapeutic areas: Immunology, Oncology
Post-Humira, AbbVie reps are driving Skyrizi (IL-23) and Rinvoq (JAK inhibitor) across dermatology, rheumatology, and GI — one of the most competitive immunology markets in pharma. With Humira biosimilar erosion accelerating, field reps face high conversion pressure alongside competitive compensation and strong infrastructure support.
Key products: Skyrizi, Rinvoq, Humira, Imbruvica, Venclexta
Anonymous AbbVie pharma sales rep discussion on compensation, quota pressure, interviews, post-Humira field reality, immunology launch execution, access friction, and culture.